Background: Drug-eluting stents (DES) are currently being used widely in patients undergoing percutaneous coronary intervention (PCI). However, data comparing sirolimus-eluting stents (SES) and paclitaxel-eluting stens (PES) are still limited. We investigated the clinical outcomes of these drug-eluting stents in unselected patients treated in the daily practice. Methods: From March 2003 to March 2005, 1006 consecutive patients were treated with SES (N=576) or PES (N=430) stenting. At the present writing, six-month clinical follow-up was completed in 688 patients (68%) and survival analysis was performed for this population. Patients treated with different kinds of stent including bare metal stents were excluded. Results: There was no difference of clinical parameters between two groups. Although there was no difference of cardiac death rate between two stents, major adverse events (MACE)-free survival rate at 6 month and 1 year was significantly higher in SES (97.4%, 95.2%) than in PES (93.9%, 85.2%) (log-rank p<0.001). Revascularization-free survival rate at 6 month and 1 year was also significantly higher in SES (98.6%, 97.1%) than in PES (96.9%, 88.8%) (log-rank p=0.001). However, subacute thrombosis was only identified in SES group (6 cases, 0.87%). Conclusion: Despite higher incidence of subacute thrombosis in SES group, our results show that SES may have better clinical outcomes compared with PES.